Edition:
United States

GW Pharmaceuticals PLC (GWPH.OQ)

GWPH.OQ on NASDAQ Stock Exchange Global Market

151.01USD
21 Jun 2018
Change (% chg)

$-1.52 (-1.00%)
Prev Close
$152.53
Open
$154.76
Day's High
$155.60
Day's Low
$150.74
Volume
73,097
Avg. Vol
101,427
52-wk High
$164.58
52-wk Low
$95.65

Chart for

About

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers... (more)

Overall

Beta: 2.60
Market Cap(Mil.): $4,135.78
Shares Outstanding(Mil.): 2.31
Dividend: --
Yield (%): --

Financials

  GWPH.OQ Industry Sector
P/E (TTM): -- 244.89 34.04
EPS (TTM): -8.41 -- --
ROI: -37.10 -5.30 13.11
ROE: -38.68 -6.83 15.11

BRIEF-GW Pharmaceuticals Qtrly Loss Per ADS 312.0 Cents

* GW PHARMACEUTICALS PLC REPORTS FISCAL SECOND QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL PROGRESS

May 08 2018

GW Pharma gets FDA panel nod, first cannabis-based drug nearing approval

An advisory panel to the U.S. Food and Drug Administration on Thursday unanimously voted in favor of approving the first cannabis-derived medicine in the country, a childhood epilepsy treatment developed by GW Pharma.

Apr 19 2018

UPDATE 2-GW Pharma gets FDA panel nod, first cannabis-based drug nearing approval

* Cowen analysts expect $1.3 bln in sales by 2022 (Adds details, analyst comment, estimates, background)

Apr 19 2018

BRIEF-GW Pharma Announces Unanimous Positive Result Of FDA Advisory Committee Meeting

* GW PHARMACEUTICALS AND U.S. SUBSIDIARY GREENWICH BIOSCIENCES ANNOUNCES THE UNANIMOUS POSITIVE RESULT OF FDA ADVISORY COMMITTEE MEETING FOR FIRST PLANT-BASED PHARMACEUTICAL CANNABIDIOL TREATMENT FOR SEIZURES IN PATIENTS WITH TWO RARE, SEVERE FORMS OF EPILEPSY

Apr 19 2018

BRIEF-GW Pharma Says Presenting CBD-OS Product In Advisory Committee Meeting With FDA On April 19

* GW PHARMACEUTICALS SAYS PRESENTING CBD-OS PRODUCT (EPIDIOLEX) IN ADVISORY COMMITTEE MEETING WITH FDA ON APRIL 19 - SEC FILING Source text: (https://bit.ly/2HK1BW3) Further company coverage:

Apr 19 2018

BRIEF-GW Pharmaceuticals Announces Receipt Of Notices Of Allowance By USPTO

* GW PHARMACEUTICALS ANNOUNCES RECEIPT OF NOTICES OF ALLOWANCE BY THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) FOR FIVE NEW EPIDIOLEX® (CANNABIDIOL) PATENTS Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 13 2018

BRIEF-GW Pharmaceuticals Receives Orphan Drug Designation From EMA For Cannabidiol For The Treatment Of Tuberous Sclerosis

* GW PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM THE EUROPEAN MEDICINES AGENCY (EMA) FOR CANNABIDIOL FOR THE TREATMENT OF TUBEROUS SCLEROSIS

Feb 27 2018

BRIEF-GW Pharma Says Mid Stage Study Of Seizures Drug Failed Main Goal

* GW PHARMACEUTICALS ANNOUNCES PRELIMINARY RESULTS OF PHASE 2A STUDY FOR ITS PIPELINE COMPOUND GWP42006

Feb 21 2018

BRIEF-GW Pharmaceuticals Announces EMA Accepts Epidiolex Marketing Authorization Application For Review

* GW PHARMACEUTICALS ANNOUNCES THE EUROPEAN MEDICINES AGENCY (EMA) ACCEPTS EPIDIOLEX® (CANNABIDIOL) MARKETING AUTHORIZATION APPLICATION (MAA) FOR REVIEW

Feb 05 2018

BRIEF-GW Pharma Announces Acceptance Of NDA Filing For Epidiolex (Cannabidiol)

* GW PHARMACEUTICALS ANNOUNCES ACCEPTANCE OF NDA FILING FOR EPIDIOLEX® (CANNABIDIOL) IN THE TREATMENT OF LENNOX-GASTAUT SYNDROME AND DRAVET SYNDROME Source text for Eikon: Further company coverage:

Dec 28 2017

Earnings vs. Estimates